Becton Dickinson & Co

BD insider sales show routine liquidity moves, not panic: Neal Shana Carol’s 1,146‑share sale keeps holdings high, suggesting steady confidence amid BD’s strategic shifts.

Michael Feld’s small 75‑share sale at $156.83 shows routine insider portfolio rebalancing, not a confidence hit—Becton‑Dickinson remains solid for long‑term investors.

Insider sale of 75 Becton Dickinson shares by Chief Revenue Officer Michael Feld shows a routine, small‑scale trade—no red flag yet for BDX investors.

BDX insider holding shows confidence in future growth amid high P/E and volatile market, hinting at a possible rally before Q1 earnings.

BDX insider buying of rights signals long‑term confidence as Becton‑Dickinson pivots to high‑margin diagnostics; investors see modest growth potential.

Insider buying spree at Becton‑Dickinson signals executive confidence in its BD‑Waters merger and new diagnostics launch, offering a bullish outlook for investors.

Michael Feld’s small Becton Dickinson stock sales amid the Waters merger reveal a cautious, portfolio‑balancing move rather than a warning sign, highlighting strategic shifts and post‑spin‑off opportunities for investors.

Spikner’s $0 sale of 84 Becton Dickinson shares is a routine tax move, not a strategic shift, amid routine insider buying and selling.

Insider buying by Becton Dickinson’s EVP signals cautious optimism: a strategic 3,054‑share purchase amid FDA clearance of EnCompass and a bullish pipeline.